# Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

> **NCT05846750** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 59 (estimated)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT05846750
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05846750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05846750, "Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05846750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*